Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Oberarzt/-ärztin, Klinik für Dermatologie
Aktuelle Veranstaltungen
-
2023 SS
Vergangene Veranstaltungen (max. 10)
-
2022 WS
-
2022 SS
-
2021 WS
-
2021 SS
-
2020 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 4,ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Characterisation and outcome of RAC1 mutated melanomaIn: European Journal of Cancer (EJC) Jg. 183 (2023) S. 1 - 10ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 181 (2023) S. 188 - 197ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 186 (2023) S. 12 - 21ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsIn: Med Jg. 4 (2023) Nr. 2, S. 113 - 129.e7ISSN: 2666-6340Online Volltext: dx.doi.org/ (Open Access)
-
The Latest Option: Nivolumab and Relatlimab in Advanced MelanomaIn: Current Oncology Reports (2023) in pressISSN: 1534-6269; 1523-3790Online Volltext: dx.doi.org/ (Open Access)
-
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch : A Multicenter, Retrospective StudyIn: Cancers Jg. 15 (2023) Nr. 5,ISSN: 2072-6694Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : Final results of a randomised, double-blind, phase 2 trialIn: Lancet Jg. 400 (2022) Nr. 10358, S. 1117 - 1129ISSN: 1474-547X; 0140-6736; 0023-7507Online Volltext: dx.doi.org/
-
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment : A prospective singlecenter study investigating seroconversion ratesIn: Frontiers in Oncology Jg. 12 (2022)ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
CTLA-4 Blockade Resistance after Relatlimab and NivolumabIn: The New England Journal of Medicine Jg. 386 (2022) Nr. 17, S. 1668 - 1669ISSN: 1533-4406; 0028-4793Online Volltext: dx.doi.org/
-
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis : A retrospective multicentre cohort studyIn: European Journal of Cancer (EJC) Jg. 175 (2022) S. 224 - 235ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/ (Open Access)
-
Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia : divergent outcomes in two men treated with PD-1 inhibitorsIn: Journal of the European Academy of Dermatology and Venereology Jg. 36 (2022) Nr. S1: Anti PD-1 Therapy of Advanced Cutaneous Squamous Cell Carcinoma, S. 41 - 44ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ (Open Access)
-
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma : a retrospective multicentre analysisIn: European Journal of Cancer (EJC) Jg. 162 (2022) S. 22 - 33ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotypeIn: Clinical and Translational Medicine Jg. 12 (2022) Nr. 11,ISSN: 2001-1326Online Volltext: dx.doi.org/ (Open Access)
-
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinomaIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 1,ISSN: 2051-1426Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsIn: Pigment Cell and Melanoma Research Jg. 35 (2022) Nr. 6, S. 573 - 586ISSN: 1755-1471; 1755-148XOnline Volltext: dx.doi.org/ (Open Access)
-
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitisIn: Data in Brief Jg. 45 (2022)ISSN: 2352-3409Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanomaIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 7,ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanomaIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 7,ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalIn: Cancers Jg. 14 (2022) Nr. 9,ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsIn: Cancers Jg. 14 (2022) Nr. 17,ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsIn: International Journal of Cancer (2022) in pressISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access)
-
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentIn: European Journal of Cancer (EJC) Jg. 166 (2022) S. 60 - 72ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 6,ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma : A multicenter study of the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 11,ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Management of partial and non-responding cutaneous squamous cell carcinomaIn: Journal of the European Academy of Dermatology and Venereology Jg. 36 (2022) Nr. S1, S. 29 - 34ISSN: 0926-9959; 1468-3083Online Volltext: dx.doi.org/ (Open Access)
-
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaIn: Cancer Imaging Jg. 22 (2022) Nr. 1,ISSN: 1470-7330; 1740-5025Online Volltext: dx.doi.org/ (Open Access)
-
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant MelanomaIn: Clinical Cancer Research Jg. 28 (2022) Nr. 14, S. 3002 - 3010ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/ (Open Access)
-
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts : Implications for Adjuvant TreatmentIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 32, S. 3741 - 3749ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ (Open Access)
-
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 3, S. 396 - 398ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapyIn: ESC Heart Failure (2022) in pressISSN: 2055-5822Online Volltext: dx.doi.org/ (Open Access)
-
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyIn: European Journal of Cancer (EJC) Jg. 161 (2022) S. 99 - 107ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapyIn: European Heart Journal Jg. 43 (2022) Nr. 4, S. 316 - 329ISSN: 0195-668X; 1522-9645Online Volltext: dx.doi.org/
-
The Prognostic Relevance of PMCA4 Expression in Melanoma : Gender Specificity and Implications for Immune Checkpoint InhibitionIn: International Journal of Molecular Sciences (IJMS) Jg. 23 (2022) Nr. 6,ISSN: 1422-0067; 1661-6596Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition : Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 ImmunohistochemistryIn: Frontiers in Oncology Jg. 11 (2021)ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Case Report : Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant MelanomaIn: Frontiers in Oncology Jg. 11 (2021) S. 637185ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesIn: European Journal of Cancer (EJC) Jg. 152 (2021) S. 139 - 154ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionIn: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. 1, S. e001931ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer : A retrospective analysis of 47 casesIn: European Journal of Cancer (EJC) Jg. 150 (2021) S. 119 - 129ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaIn: Annals of Oncology Jg. 32 (2021) Nr. 7, S. 917 - 925ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapyIn: eNeurologicalSci Jg. 22 (2021) S. 100324ISSN: 2405-6502Online Volltext: dx.doi.org/ (Open Access)
-
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic MelanomaIn: Frontiers in Oncology Jg. 11 (2021)ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Discontinuation of braf/mek-directed targeted therapy after complete remission of metastatic melanoma : a retrospective multicenter adoreg studyIn: Cancers Jg. 13 (2021) Nr. 10, S. 2312ISSN: 2072-6694Online Volltext: dx.doi.org/ (Open Access)
-
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma : A Retrospective Multicenter DeCOG StudyIn: Frontiers in Oncology Jg. 11 (2021)ISSN: 2234-943XOnline Volltext: dx.doi.org/ (Open Access)
-
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV⁶⁰⁰ mutant melanoma : safety and tolerability results from the phase I IMMU-TARGET trialIn: The European Journal of Cancer Jg. 158 (2021) S. 72 - 84ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Factors influencing the adjuvant therapy decision : Results of a real-world multicenter data analysis of 904 melanoma patientsIn: Cancers Jg. 13 (2021) Nr. 10, S. 2319ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition : A Descriptive Observational Retrospective Multicenter AnalysisIn: Frontiers in Oncology Jg. 11 (2021)ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Hematological immune related adverse events after treatment with immune checkpoint inhibitorsIn: European Journal of Cancer Jg. 147 (2021) S. 170 - 181ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/
-
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyIn: European Journal of Cancer (EJC) Jg. 153 (2021) S. 168 - 178ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy : a multicentre, retrospective, cohort studyIn: The Lancet Oncology Jg. 22 (2021) Nr. 6, S. 836 - 847ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/
-
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma : Authors' replyIn: The Lancet Oncology Jg. 22 (2021) Nr. 8, S. E343 - E344ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/
-
Kutanes Angiosarkom mit klinischem Bild eines Quincke-ÖdemsIn: Der Hautarzt Jg. 72 (2021) Nr. 9, S. 801 - 804ISSN: 1432-1173; 0017-8470Online Volltext: dx.doi.org/ (Open Access)
-
Leptomeningeal disease from melanoma : Poor prognosis despite new therapeutic modalitiesIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 395 - 404ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy : A multicentre study of 90 patients from the German Dermatooncology GroupIn: European Journal of Cancer (EJC) Jg. 149 (2021) S. 1 - 10ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Melanoma recurrence patterns and management after adjuvant targeted therapy : A multicentre analysisIn: British Journal of Cancer (BJC) Jg. 124 (2021) Nr. 3, S. 574 - 580ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access)
-
Metastatic pigmented epithelioid melanocytoma in a 7-year-old femaleIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. 8, S. 1217 - 1219ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access)
-
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer Jg. 148 (2021) S. 340 - 347ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsIn: European Journal of Cancer (EJC) Jg. 159 (2021) S. 113 - 124ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 61 - 75ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries : A multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)In: Journal of Cancer Research and Clinical Oncology Jg. 147 (2021) Nr. 6, S. 1763 - 1771ISSN: 1432-1335; 0171-5216; 0084-5353; 0301-1585Online Volltext: dx.doi.org/ (Open Access)
-
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapyIn: European Journal of Cancer (EJC) Jg. 153 (2021) S. 213 - 222ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastasesIn: European Journal of Cancer Jg. 156 (2021) S. 149 - 163ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access)
-
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibIn: Clinical Cancer Research Jg. 27 (2021) Nr. 16, S. 4500 - 4510ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/ (Open Access)
-
SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registryIn: European Journal of Cancer Jg. 144 (2021) S. 382 - 385ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access)
-
Surveillance of patients with conjunctival melanoma in German-speaking countries : A multinational survey of the German dermatologic cooperative oncology groupIn: European Journal of Cancer (EJC) Jg. 143 (2021) S. 43 - 45ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsIn: European Journal of Cancer (EJC) Jg. 155 (2021) S. 268 - 280ISSN: 1879-0852; 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition : A multicentre retrospective analysisIn: European Journal of Cancer (EJC) Jg. 151 (2021) S. 72 - 83ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : a randomised, double-blind, placebo-controlled, phase 2 trialIn: The Lancet Jg. 395 (2020) Nr. 10236, S. 1558 - 1568ISSN: 1474-547X; 0140-6736Online Volltext: dx.doi.org/
-
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 26 (2020) Nr. 7, S. 1147ISSN: 1546-170X; 1078-8956Online Volltext: dx.doi.org/ (Open Access)
-
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathologyIn: PLoS Pathogens Jg. 16 (2020) Nr. 3,ISSN: 1553-7374; 1553-7366Online Volltext: dx.doi.org/ (Open Access)
-
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis : A DeCOG∗ study in 380 patientsIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 1,ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy : Increased rate and mimicker of metastasisIn: European Journal of Cancer Jg. 131 (2020) S. 18 - 26ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade : A Case ReportIn: Frontiers in Oncology Jg. 10 (2020) S. 592609ISSN: 2234-943XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
ECG Changes in Melanoma Patients Undergoing Cancer Therapy : Data from the ECoR RegistryIn: Journal of Clinical Medicine (JCM) Jg. 9 (2020) Nr. 7,ISSN: 2077-0383Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaIn: Annals of Oncology Jg. 31 (2020) Nr. 1, S. 144 - 152ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Fatal swelling of the groin – Clear cell sarcoma : A rare but important differential diagnosis to malignant melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. 10, S. 1165 - 1168ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access)
-
GNAQ and GNA11 mutant nonuveal melanoma : A subtype distinct from both cutaneous and uveal melanomaIn: British Journal of Dermatology: BJD Jg. 183 (2020) Nr. 5, S. 928 - 939ISSN: 1365-2133; 0007-0963; 0366-2845Online Volltext: dx.doi.org/ (Open Access)
-
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy : A retrospective multicenter DeCOG study of 84 patientsIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 2, S. e000897ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Immuntherapie beim malignen MelanomIn: Der Internist Jg. 61 (2020) Nr. 7, S. 669 - 675ISSN: 1432-1289; 0020-9554Online Volltext: dx.doi.org/ (Open Access)
-
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma : A multicenter retrospective cohort study of the DeCOGIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 1, S. e000395ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
Malignes Melanom : Stellenwert der BRAF-Inhibition beim malignen MelanomIn: Der Onkologe Jg. 26 (2020) Nr. 8, S. 713 - 720ISSN: 1433-0415; 0947-8965Online Volltext: dx.doi.org/
-
Malignes MelanomIn: Der Hautarzt Jg. 71 (2020) S. 63 - 77ISSN: 1432-1173; 0017-8470Online Volltext: dx.doi.org/
-
Malignes MelanomIn: Der Onkologe Jg. 26 (2020) Nr. 1, S. 75 - 87ISSN: 0947-8965; 1433-0415Online Volltext: dx.doi.org/
-
Malignes MelanomIn: Der Pathologe Jg. 41 (2020) Nr. 3, S. 281 - 292ISSN: 0172-8113Online Volltext: dx.doi.org/
-
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD-1-Antikörper beim metastasierten Melanom : ein UpdateIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. 6, S. 582 - 609ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access)
-
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma : real-world data of a retrospective, multicenter studyIn: European Journal of Cancer Jg. 138 (2020) S. 125 - 132ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an updateIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. 6, S. 582 - 609ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access)
-
Survival of patients with advanced metastatic melanoma : The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019In: European Journal of Cancer Jg. 130 (2020) S. 126 - 138ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma : A multi-institutional retrospective studyIn: The Journal of Dermatology Jg. 47 (2020) Nr. 6, S. 629 - 635ISSN: 1346-8138; 0385-2407Online Volltext: dx.doi.org/
-
Checkpoint Inhibitors : The diagnosis and treatment of side effectsIn: Deutsches Ärzteblatt international Jg. 116 (2019) Nr. 8, S. 119 - 126ISSN: 1866-0452Online Volltext: dx.doi.org/ (Open Access)
-
Clinical and genetic analysis of melanomas arising in acral sitesIn: European Journal of Cancer Jg. 119 (2019) S. 66 - 76ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access)
-
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases : a real-life multicenter studyIn: Melanoma Research Jg. 29 (2019) Nr. 1, S. 65 - 69ISSN: 0960-8931; 1473-5636Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access)
-
Combined immune checkpoint blockade for metastatic uveal melanoma : a retrospective, multi-center studyIn: Journal for ImmunoTherapy of Cancer Jg. 7 (2019) Nr. 1, Article-No: 299ISSN: 2051-1426Online Volltext: dx.doi.org/ (Open Access)
-
High PD-1 or PD-L1 Concentrations in the Serum of Melanoma Patients are predictive for reduced Therapeutic Success of PD-1 InhibitionIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 17 (2019) Nr. Suppl. 5, S. 7 - 7ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanomaIn: European Journal of Cancer Jg. 119 (2019) S. 18 - 29ISSN: 0959-8049; 1879-0852; 1879-2995; 0964-1947; 0277-5379Online Volltext: dx.doi.org/
-
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesIn: European Journal of Cancer Jg. 110 (2019) S. 11 - 20ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access)
-
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 25 (2019) Nr. 12, S. 1916 - 1927ISSN: 1546-170X; 1078-8956Online Volltext: dx.doi.org/ (Open Access)
-
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition : a case seriesIn: Cancer Immunology, Immunotherapy Jg. 68 (2019) Nr. 6, S. 983 - 990ISSN: 0340-7004; 1432-0851Online Volltext: dx.doi.org/
-
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks : An international rare cancers initiative (IRCI) ocular melanoma studyIn: Annals of Oncology Jg. 30 (2019) Nr. 8, S. 1370 - 1380ISSN: 0923-7534Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Metastatic Merkel cell carcinoma and myasthenia gravis : contraindication for therapy with immune checkpoint inhibitors?In: Journal for ImmunoTherapy of Cancer Jg. 7 (2019) Nr. 1, S. 141ISSN: 2051-1426Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitorsIn: The European Journal of Cancer Jg. 106 (2019) S. 12 - 23ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL) : a multicentre, open-label, randomised, controlled phase II trialIn: Annals of Oncology Jg. 30 (2019) Nr. 2, S. 317 - 324ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic factors for pulmonary metastasectomy in malignant melanoma : Size mattersIn: European Journal of Cardio-Thoracic Surgery Jg. 56 (2019) Nr. 6, S. 1104 - 1109ISSN: 1873-734X; 1010-7940; 1567-4258; 1878-3309Online Volltext: dx.doi.org/ (Open Access)
-
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV⁶⁰⁰E inhibition in melanomaIn: European Journal of Cancer Jg. 109 (2019) S. 137 - 153ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case reportIn: BMC Cancer Jg. 19 (2019) Nr. 1, S. 995ISSN: 1471-2407Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Targeted Therapy in Advanced Melanoma With Rare BRAF MutationsIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 33, S. 3142 - 3151ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ (Open Access)
-
Tolerability of BRAF/MEK inhibitor combinations : Adverse event evaluation and managementIn: ESMO Open Jg. 4 (2019) Nr. 3, S. e000491ISSN: 2059-7029Online Volltext: dx.doi.org/ (Open Access)
-
Treatment in metastatic melanoma : Time to re-thinkIn: Annals of Oncology Jg. 30 (2019) Nr. 4, S. 501 - 503ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access)
-
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionIn: European journal of cancer Jg. 104 (2018) S. 137 - 144ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/
-
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patientsIn: British Journal of Cancer (BJC) Jg. 118 (2018) Nr. 6, S. 785 - 792ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access)
-
Dose-dependent toxicity of ipilimumab in metastatic melanomaIn: European Journal of Cancer Jg. 95 (2018) S. 104 - 108ISSN: 1879-2995; 0959-8049Online Volltext: dx.doi.org/
-
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disordersIn: Cancer Immunology, Immunotherapy Jg. 67 (2018) Nr. 5, S. 825 - 834ISSN: 0340-7004; 1432-0851Online Volltext: dx.doi.org/
-
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockadeIn: European Journal of Cancer Jg. 99 (2018) S. 58 - 65ISSN: 0959-8049; 1879-0852Online Volltext: dx.doi.org/
-
Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanomaIn: Cancer Medicine Jg. 7 (2018) Nr. 1, S. 95 - 104ISSN: 2045-7634Online Volltext: dx.doi.org/ (Open Access)
-
Sebaceous tumours: more than skin deepIn: Gut Jg. 67 (2018) Nr. 11, S. 2045 - 2053ISSN: 0017-5749; 1468-3288Online Volltext: dx.doi.org/
-
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : A retrospective multicenter studyIn: OncoTarget Jg. 9 (2018) Nr. 76, S. 34336 - 34346ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access)
-
The safety and efficacy of dabrafenib and trametinib for the treatment of melanomaIn: Expert Opinion on Drug Safety Jg. 17 (2018) Nr. 1, S. 73 - 87ISSN: 1744-764X; 1474-0338Online Volltext: dx.doi.org/
-
The utility of chemotherapy after immunotherapy failure in metastatic melanoma : A multicenter case series.In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 15 Suppl., S. e21588ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4) : Evaluation and management of adverse drug reactionsIn: Cancer Treatment Reviews Jg. 57 (2017) S. 36 - 49ISSN: 1532-1967; 0305-7372Online Volltext: dx.doi.org/
-
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisIn: European Journal of Cancer Jg. 86 (2017) S. 248 - 256ISSN: 1879-2995; 0959-8049; 1879-0852; 0014-2964Online Volltext: dx.doi.org/
-
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanomaIn: European Journal of Cancer Jg. 83 (2017) S. 142 - 145ISSN: 0959-8049; 1879-2995Online Volltext: dx.doi.org/
-
IRF4 rs12203592 functional variant and melanoma survivalIn: International Journal of Cancer Jg. 140 (2017) Nr. 8, S. 1845 - 1849ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/
-
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaIn: European Journal of Cancer Jg. 75 (2017) S. 47 - 55ISSN: 1879-2995; 0959-8049; 1879-0852; 0014-2964Online Volltext: dx.doi.org/
-
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityIn: European Journal of Cancer Jg. 75 (2017) S. 24 - 32ISSN: 1879-2995; 0959-8049; 0014-2964; 1879-0852Online Volltext: dx.doi.org/
-
Radiosensibilisierung durch BRAF InhibitorenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 15 (2017) Nr. 7, S. 703 - 708ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Radiosensitization by BRAF inhibitorsIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 15 (2017) Nr. 7, S. 703 - 708ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
SF3B1 and BAP1 mutations in blue nevus-like melanomaIn: Modern Pathology Jg. 30 (2017) Nr. 7, S. 928 - 939ISSN: 1530-0285; 0893-3952Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIn: OncoTarget Jg. 8 (2017) Nr. 25, S. 40683 - 40692ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access)
-
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyIn: European Journal of Cancer Jg. 60 (2016) S. 190 - 209ISSN: 1879-0852; 1879-2995Online Volltext: dx.doi.org/
-
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyIn: Cancer Treatment Reviews Jg. 45 (2016) S. 7 - 18ISSN: 1532-1967; 0305-7372Online Volltext: dx.doi.org/
-
Gebrauch von Komplementärmedizin bei Patienten mit metastasierendem Melanom unter Therapie mit Ipilimumab innerhalb einer klinischen StudieIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 14 (2016) Nr. 5, S. 508 - 513ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survivalIn: International Journal of Cancer Jg. 139 (2016) Nr. 6, S. 1297 - 1302ISSN: 0020-7136; 1097-0215Online Volltext: dx.doi.org/ (Open Access)
-
Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosisIn: Medicine Jg. 95 (2016) Nr. 29, S. e4332ISSN: 0025-7974; 1536-5964Online Volltext: dx.doi.org/ (Open Access)
-
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 14 (2016) Nr. 7, S. 662 - 681ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Medikamentöse Therapie des metastasierten malignen MelanomsIn: Arzneimitteltherapie Jg. 34 (2016) Nr. 1-2, S. 14 - 22ISSN: 0723-6913
-
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 14 (2016) Nr. 7, S. 662 - 683ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyIn: European Journal of Cancer Jg. 60 (2016) S. 210 - 225ISSN: 1879-0852Online Volltext: dx.doi.org/
-
Oncogene status as a diagnostic tool in ocular and cutaneous melanomaIn: European Journal of Cancer Jg. 57 (2016) S. 112 - 117ISSN: 0959-8049Online Volltext: dx.doi.org/
-
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous systemIn: Journal of Neuro-Oncology Jg. 127 (2016) Nr. 3, S. 435 - 444ISSN: 1573-7373; 0167-594XOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma : pretreatment impacts survivalIn: Annals of Oncology Jg. 26 (2015) Nr. 3, S. 573 - 582ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access)
-
Acquired BRAF inhibitor resistance : A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsIn: European Journal of Cancer Jg. 51 (2015) Nr. 18, S. 2792 - 2799ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Analysis of SDHD promoter mutations in various types of melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 13 (2015) Nr. Suppl. 2, S. 11ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Analysis of SDHD promoter mutations in various types of melanomaIn: OncoTarget Jg. 6 (2015) Nr. 28, S. 25868 - 25882ISSN: 1949-2553Online Volltext: dx.doi.org/ (Open Access)
-
Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?In: Melanoma Research Jg. 25 (2015) Nr. 4, S. 362 - 366ISSN: 0960-8931; 1473-5636Online Volltext: dx.doi.org/
-
Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of InfectionIn: PLoS ONE Jg. 10 (2015) Nr. 4, S. e0124590ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Erythema nodosum-like lesions during BRAF inhibitor therapy : report on 16 new cases and review of the literatureIn: Journal of the European Academy of Dermatology and Venereology Jg. 29 (2015) Nr. 9, S. 1797 - 1806ISSN: 1468-3083; 0926-9959Online Volltext: dx.doi.org/
-
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaIn: Science Jg. 350 (2015) Nr. 6257, S. 207 - 211ISSN: 0036-8075; 1095-9203Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanomaIn: Journal of Translational Medicine Jg. 13 (2015) Nr. 1, S. 351ISSN: 1479-5876Online Volltext: dx.doi.org/ (Open Access)
-
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaIn: PLoS ONE Jg. 10 (2015) Nr. 3, S. e0118564ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsIn: Annals of Oncology Jg. 26 (2015) Nr. 6, S. 1238 - 1244ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ (Open Access)
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.In: Annals of Oncology Jg. 26 (2015) Nr. 1, S. 250 - 251ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/
-
Therapie des malignen MelanomsIn: Der Onkologe Jg. 21 (2015) Nr. 10, S. 965 - 974ISSN: 0947-8965Online Volltext: dx.doi.org/
-
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 747 - 753ISSN: 1569-8041Online Volltext: dx.doi.org/
-
Genetic and clinico-pathologic analysis of metastatic uveal melanomaIn: Modern Pathology Jg. 27 (2014) Nr. 2, S. 175 - 183ISSN: 1530-0285; 0893-3952Online Volltext: dx.doi.org/
-
Incidence of new primary melanomas after diagnosis of stage III and IV melanomaIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 8, S. 816 - 823ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Kutane Nebenwirkungen der medikamentösen Tumortherapie mit BRAF- und MEK-InhibitorenIn: Der Hautarzt Jg. 65 (2014) Nr. 7, S. 582 - 589ISSN: 0017-8470; 1432-1173Online Volltext: dx.doi.org/
-
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsIn: Clinical Cancer Research Jg. 20 (2014) Nr. 16, S. 4251 - 4261ISSN: 1557-3265Online Volltext: dx.doi.org/
-
Reply to M. Perier-Muzet et al [Safety and Management of New Primary Melanomas During Receipt of BRAF Inhibitors ]In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 28, S. 3203 - 3204ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rashIn: Journal of the European Academy of Dermatology and Venereology Jg. 28 (2014) Nr. 12, S. 1685 - 1689ISSN: 1468-3083Online Volltext: dx.doi.org/
-
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaIn: Journal of the National Cancer Institute Jg. 106 (2014) Nr. 9,ISSN: 1460-2105; 0027-8874Online Volltext: dx.doi.org/
-
TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomasIn: Modern Pathology Jg. 27 (2014) Nr. 4, S. 502 - 508ISSN: 1530-0285; 0893-3952Online Volltext: dx.doi.org/ (Open Access)
-
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic MelanomaIn: Cancer Discovery Jg. 4 (2014) Nr. 1, S. 94 - 109ISSN: 2159-8290; 2159-8274Online Volltext: dx.doi.org/
-
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition : MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsIn: European Journal of Cancer Jg. 50 (2014) Nr. 2, S. 406 - 410ISSN: 0959-8049Online Volltext: dx.doi.org/
-
23. Jahrestagung der Arbeitsgemeinschaft Dermatologische Onkologie (ADO) - Deutscher Hautkrebskongress in EssenIn: JDDG - Journal of the German Society of Dermatology Jg. 11 (2013) Nr. 12, S. 1220 - 1221ISSN: 1610-0379; 1610-0387Online Volltext: dx.doi.org/
-
Autoimmuno-hypophysitis, Autoimmuno-colitis and Autoimmuno-hepatitis in a Patient with metastatic Melanoma during Therapy with CTLA-4 Antibody IpilimumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 11 (2013) Nr. 9, S. 932ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicityIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 30, S. 3844 - 3845ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Conjunctival Melanomas Harbor BRAF and NRAS Mutations—ResponseIn: Clinical Cancer Research Jg. 19 (2013) Nr. 22, S. 6331 - 6332ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/
-
Hautkrebsforschung reloaded : Paradigmenwechsel in der DermatoonkologieIn: Unikate: Berichte aus Forschung und Lehre (2013) Nr. 44: Medizin: 50 Jahre Universitätsklinikum Essen, S. 136 - 143ISBN: 978-3-934359-44-4 ISSN: 0944-6060; 1869-3881Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Immune-related hypophysitis in three patients with metastatic melanoma undergoing Ipilimumab treatmentIn: Experimental and Clinical Endocrinology & Diabetes Jg. 121 (2013) S. P10ISSN: 0947-7349Online Volltext: dx.doi.org/
-
Isolated cerebral susceptibility artefacts in patients with malignant melanoma : Metastasis or not?In: European Radiology Jg. 23 (2013) Nr. 9, S. 2622 - 2627ISSN: 0938-7994; 1432-1084Online Volltext: dx.doi.org/
-
Kombination von BRAF-Inhibitoren (BRAFi) und zerebraler Bestrahlung bei Patienten mit metastasiertem Melanom : Eine mögliche Behandlungsoption für neu aufgetretene oder pro-grediente Hirnmetastasen unter Therapie mit BRAF-InhibitorenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 11 (2013) Nr. 9, S. 952 - 952ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Lack of SF3B1 R625 mutations in cutaneous melanomaIn: Diagnostic Pathology Jg. 8 (2013) S. 87ISSN: 1746-1596Online Volltext: dx.doi.org/ (Open Access)
-
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinomaIn: PLoS ONE Jg. 8 (2013) Nr. 11, S. e80354ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumoursIn: British Journal of Cancer (BJC) Jg. 109 (2013) Nr. 2, S. 497 - 501ISSN: 1532-1827; 0007-0920Online Volltext: dx.doi.org/ (Open Access)
-
Advances and perspectives in immunotherapy of melanomaIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 10, S. x104 - x108ISSN: 0923-7534; 1569-8041Online Volltext: dx.doi.org/ Online Volltext
-
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF InhibitionIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. 19, S. 2375 - 2383ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Current advances and perspectives in the treatment of advanced melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 10 (2012) Nr. 5, S. 319 - 325ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB) : A multicentre, open-label, phase 2 trialIn: The Lancet Oncology Jg. 13 (2012) Nr. 11, S. 1087 - 1095ISSN: 1470-2045; 1474-5488Online Volltext: dx.doi.org/
-
Immuntherapie des MelanomsIn: Der Onkologe Jg. 18 (2012) Nr. 9, S. 801 - 807ISSN: 0947-8965; 1433-0415Online Volltext: dx.doi.org/
-
Immuntherapie des MelanomsIn: Der Hautarzt Jg. 63 (2012) Nr. 12, S. 952 - 960ISSN: 1432-1173Online Volltext: dx.doi.org/
-
Nebenwirkungsmanagement von AfatinibIn: TumorDiagnostik & Therapie Jg. 33 (2012) Nr. 3, S. 154 - 161ISSN: 1439-1279; 1439-1279Online Volltext: dx.doi.org/
-
Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its ManagementIn: Archives of Dermatology Jg. 148 (2012) Nr. 3, S. 357 - 361ISSN: 1538-3652Online Volltext: dx.doi.org/
-
Side effects of systemic oncological therapies in dermatologyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 10 (2012) Nr. 7, S. 475 - 486ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
EGFR-Inhibitoren und Multityrosinkinaseinhibitoren : Interdisziplinäre Behandlung der kutanen NebenwirkungenIn: Deutsche Medizinische Wochenschrift - DMW Jg. 136 (2011) Nr. 1-2, S. 39 - 44ISSN: 1439-4413; 0012-0472; 1437-5982Online Volltext: dx.doi.org/
-
Failure to detect production of IL-10 by activated human neutrophilsIn: Nature Immunology Jg. 12 (2011) Nr. 11, S. 1017 - 1018ISSN: 1529-2916; 1529-2908Online Volltext: dx.doi.org/
-
PLX4032 : does it keep its promise for metastatic melanoma treatment?In: Expert Opinion on Investigational Drugs Jg. 19 (2010) Nr. 11, S. 1439 - 1449ISSN: 1354-3784; 1744-7658Online Volltext: dx.doi.org/
-
Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients : a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 13 - 14ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Early safety signals from nivolumab in the adjuvant treatment of real-world melanoma patients derived from the German prospective non-interventional study NICO
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 18 - 19ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Efficacy and safety of "second adjuvant" therapy with BRAF/MEK inhibitors after resection of recurrent melanoma following adjuvant PD-1–based immunotherapyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9575ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma : Interim analysis of the ImmunoCobiVem studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9548ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Efficacy of ipilimumab 3mg/kg following progression on low dose ipilimumab in metastatic melanomaIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. e21533ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Genetic and methylation analysis of CTNNB1 mutations in benign and malignant melanocytic lesions
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 84ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Im Plasma zirkulierende zellfreie mRNA ermöglicht die minimal-invasive und Genotyp-unabhängige Therapieüberwachung bei Patienten mit Melanom
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 12 - 13ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Immune Checkpoint Inhibitor (ICI)-associated Pulmonary Manifestations (ICI-LM): Characterization of HRCT and BAL Findings
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie Jg. 76 (2022) Nr. Supplement 1, S. S52ISSN: 0934-8387; 1438-8790Online Volltext: dx.doi.org/ -
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 29 - 30ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Klinische und pathologische Merkmale des familiären Melanoms bei Keimbahn-TERT-Promotorvarianten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 6ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity : A multicenter case seriesIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 2665ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Molekularpathologie und Methylierungsprofile als diagnostische Unterstützung zur Differenzierung von Klarzellsarkomen und melanozytären Tumoren
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 88ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrenceIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9570ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Partielle Remission auf Cemiplimab eines beidseitig Orbitae-infiltrierenden Basalzellkarzinoms des Mittelgesichts
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 44 - 45ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Predictors of long-term survival of stage IV melanoma patients : a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 16 - 17ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
REINA - Retrospective Multicenter ADOReg Evaluation of Ipilimumab plus Nivolumab in Avelumab-refractory Merkel cell carcinoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 21ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Therapiemanagement des ersten Rezidivs nach adjuvanter Therapie im Stadium III : multizentrische real-world Daten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 3ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Tolerability and efficacy of BRAF and MEK inhibitors for metastasized melanoma after intra-class switch : a multicenter, retrospective study
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 28 - 29ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Which patients should receive adjuvant treatment : an analysis of stage IIA-IIIA patients of the CMMR
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 19ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ -
Additional Benefit of FDG-PET when Discontinuing Immune Checkpoint Inhibitor Therapy in Patients with metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 75 - 76ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)In: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 873 - S874ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Bronchoalveolar lavage fluid (BALF) findings in patients with immune checkpoint inhibitor (ICI)-associated interstitial pneumonia (IP)In: European Respiratory Journal (ERJ) (2021)ISSN: 1399-3003; 0903-1936Online Volltext: dx.doi.org/
-
Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI)In: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 877 - S878ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Immune checkpoint-Inhibition in Patients with NRAS-mutated Melanoma compared to Patients with NRAS Wild-type Melanoma : Results of a Study on 702 Patients from the prospective, multicenter Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 59 - 60ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
PD-L1-Expression and Mutation Profile in pre-therapeutic Tumor Tissue as Predictors of the Therapeutic Success of PD-1-based Immune Checkpoint Inhibition Therapy in Patients with metastatic Melanoma : Evaluation of the prospective multicentric ADO-Study TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 19ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
PTHrP-induced hypercalcemia Psychosyndrome under Immune Checkpoint Blockade in Patients with penile Squamous Cell CarcinomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 23ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patientsIn: Journal of Clinical Oncology Jg. 39 (2021) Nr. 15_Suppl, S. 9533 - 9533ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Predictors of Super-response (CR/PR within 3 Months) under PD-1-based Immune Checkpoint Inhibition in metastatic Melanoma : A Subgroup Analysis of the prospective multicenter Study ADOREG TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 6 - 7ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
TERT Promoter Mutations associated with longer progression-free and Overall Survival under BRAF/MEK TherapyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 31ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Termination of targeted Therapy with BRAF-/MEK Inhibitors after an initial complete Response in Patients with metastatic Melanoma and its clinical Implications : A retrospective, multicenter ADOReg StudyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 15 - 16ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma : Final results from the dose-finding phase I part of the IMMU-Target trialIn: Journal of Clinical Oncology Jg. 39 (2021) Nr. 15_Suppl, S. 9532 - 9532ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Tumor PD-L1-Positivity in medical and digital Quantification predicts a favorable Patient Outcome for a PD-1-based Immune Checkpoint-Blockade in metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 58 - 59ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Agranulozytose unter Immuncheckpoint‐Blockade : Eine retrospektive, multizentrische AuswertungIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV28ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Apoptotische Gastritis nach Immuncheckpointblockade : Ein typisches histopathologisches MusterIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P12ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)In: Clinical Cancer Research Jg. 26 (2020) Nr. 18 Suppl., S. 02 - 01ISSN: 1078-0432; 1557-3265Online Volltext: dx.doi.org/
-
Delayed immune-related adverse events (irAEs) on anti-PD1-based therapyIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S761 - S762ISSN: 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Die Extracorporale Photopherese verbessert therapierefraktäre autoimmune Nebenwirkungen nach ImmuncheckpointblockadeIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV06ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Die diagnostische Bedeutung der CT-gesteuerten Punktion bei HauttumorpatientenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV49ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Die digitale Analyse der Tumor PD‐L1 Expression ist ein guter Prädiktor des Therapieerfolgs einer anti‐PD1‐basierten Immuntherapie : Eine Subgruppenanalyse der multizentrischen translationalen Studie ADOREG/TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV36ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Eindrucksvolles und schnelles Therapieansprechen eines metastasierten Adnexkarzinoms unter CemiplimabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV08ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Immun‐Checkpoint‐Blockade beim Merkelzellkarzinom : Klinische und molekulare Biomarker‐AnalyseIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV22ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapyIn: Journal of Clinical Oncology Jg. 38 (2020) Nr. 15_Suppl., S. 10005ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Melanoma recurrence after adjuvant targeted therapy : A multicenter analysisIn: Journal of Clinical Oncology Jg. 38 (2020) Nr. 15_Suppl., S. 10016ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Neoadjuvante Immun‐ und zielgerichtete Therapie bei Melanompatienten im Stadium III BIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV44ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
PD1‐Inhibitoren bei fortgeschrittenem kutanem Plattenepithelkarzinom : „Real World“‐Daten einer retrospektiven, multizentrischen StudieIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV20ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Preclinical and clinical assessment of immune checkpoint inhibitor-associated left ventricular dysfunction
ESC Congress 2020 – The Digital Experience 29 August – 1 September 2020,In: European Heart Journal Jg. 41 (2020) Nr. Supplement_2, S. 3260ISSN: 0195-668X; 1522-9645Online Volltext: dx.doi.org/ -
SERIO – Side Effect Registry Immuno‐Oncology : Nebenwirkungsregister für seltene, schwere und komplexe Nebenwirkungen von ImmuntherapienIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV27ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
The nature and management of acquired resistance to PD1-based therapy in melanomaIn: Journal of Clinical Oncology Jg. 38 (2020) Nr. 15_Suppl., S. 10014ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibitionIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S733 - S734ISSN: 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Therapieentscheidung bei Indikation zur adjuvanten Therapie des Melanoms : Multizentrische Real World DataIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV43ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Variants in CD5 and IRF4 impact into melanoma survivalIn: European Journal of Human Genetics Jg. 26 (2019) Nr. Suppl., S. 688 - 689ISSN: 1018-4813Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC) : A randomized, multicenter DeCOG/ADO studyIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9527ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Adjuvante Therapie des Merkelzellkarzinoms mit Ipilimumab im Vergleich zur Beobachtung (ADMEC) : eine randomisierte, multizentrische ADO‐Studie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 6ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Auswirkungen der überarbeiteten AJCC‐Klassifikation (8. Edition) auf das Essener Melanomkollektiv
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 61 - 62ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Autoimmunbedingte Gastritis nach Immuncheckpoint‐Blockade : eine Fallserie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 26 - 27ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
BRAF/MEK inhibition in melanoma patients with rare BRAF mutationsIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9542 - 9542ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
CCR5 Δ32 Polymorphismus als prädiktiver Marker für die Therapie mit Immuncheckpoint‐Inhibitoren beim Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 49 - 50ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Charakterisierung des Checkpoint‐Inhibitor‐assoziierten Diabetes mellitus – Erfahrungen bei 12 Patienten
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 15 - 16ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. Suppl. 6, S. 3ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Die Anzahl mutierter Melanom‐assoziierter Gene und die Expression von PD‐L1 sind unabhängige Prädiktoren der anti‐PD1 Immuntherapie ‐ eine prospektive Registerstudie der ADO (ADOREG/TRIM)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 7 - 8ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access)
-
Einfluss einer vorangegangenen Radiatio auf den Erfolg einer immunonkologischen Therapie beim metastasierten Melanom – eine retrospektive multizentrische Studie der ADO
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 28 - 29ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapyIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 9545 - 9545ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Hyponatriämie und Nephritis – seltene Nebenwirkungen von Checkpointinhibitoren bei Patienten mit metastasiertem Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 15ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 3ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Meningeosis melanomatosa : Schlechte Prognose trotz neuer Systemtherapeutika
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 11 - 12ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Mundtrockenheit unter Immuncheckpoint‐Inhibitoren: eine Analyse von 29 Patienten aus 10 deutschen Hautkrebszentren
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 10 - 11ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
NICO ‐ eine nationale, prospektive, nicht‐interventionelle Studie (NIS) mit Nivolumab als Monotherapie oder in Kombination mit Ipilimumab bei Patienten mit fortgeschrittenem (inoperablem oder metastasiertem) Melanom zur Erhebung von real‐world data
Konferenz 28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 79ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Neuromuskuläre Nebenwirkungen von Immuncheckpoint‐Inhibitoren
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 9 - 10ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Partielle Remission eines fortgeschrittenen Melanoms durch eine Kombinationstherapie mit Nivolumab und Trametinib nach Therapieversagen unter Ipilimumab + Nivolumab
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 38ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Real-world evidence in melanoma : A national, prospective, non-interventional study (NIS) of nivolumab monotherapy or in combination with ipilimumab in patients with advanced (unresected or metastatic) melanoma (NICO)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 159ISSN: 2296-5262; 2296-5270Online Volltext: dx.doi.org/ (Open Access) -
Therapieversagen der Immuncheckpoint‐Blockade mit PD1‐Antikörpern bei Patienten mit metastasierten Hauttumorerkrankungen und gleichzeitiger Immunsuppression durch eine Chronisch Lymphatische Leukämie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 28ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/ (Open Access) -
Diagnostik und Therapie der immunvermittelten Thyreoiditis unter Therapie mit Ipilimumab und NivolumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 15 (2017) Nr. Suppl. 3, S. 26 - 27ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481Online Volltext: dx.doi.org/
-
Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroupsIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, Suppl., S. 9031ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/